Rituximab is a human/murine, chimeric anti-CD20 monoclonal antibody with established
efficacy, and a favorable and well-defined safety profile in patients with various CD20 …

Adoptive cellular immunotherapy with chimeric antigen receptor (CAR) T cell has changed
the treatment landscape of B-cell non-Hodgkin's lymphoma (NHL), especially for aggressive …

Purpose Twenty percent of patients with follicular lymphoma (FL) experience progression of
disease (POD) within 2 years of initial chemoimmunotherapy. We analyzed data from the …

Follicular lymphomas (FLs) are the second most frequent subtype of nodal lymphoid
malignancies in Western Europe. The annual incidence of this disease has rapidly …

Abstract This randomized, noninferiority (NI), global, phase 3 study evaluated the efficacy
and safety of bendamustine plus rituximab (BR) vs a standard rituximab-chemotherapy …

Purpose Identifying patients at high risk of progression and early death among those with
high-tumor-burden follicular lymphoma (FL) is unsatisfactory with current prognostic models …

Background Standard treatments for indolent non-Hodgkin lymphomas are often toxic, and
most patients ultimately relapse. Lenalidomide, an immunomodulatory agent, is effective as …

Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma in the
Western hemisphere. After decades of stagnation, the natural history of FL appears to have …

Disease overview Follicular lymphoma is generally an indolent B cell lymphoproliferative
disorder of transformed follicular center B cells. Follicular lymphoma (FL) is characterized by …

Purpose The FOLL05 trial compared R-CVP (rituximab plus cyclophosphamide, vincristine,
and prednisone) with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine …